Aβ Variant Gene Therapy for Sustained Inhibition of Amyloid Polymerization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies for neurodegenerative diseases, particularly Alzheimer's, face challenges with BBB penetration and short half-lives of peptide drugs, leading to ineffective treatment of Aβ polymerization and toxicity.
Innovation Solution
A novel genetic construct encoding Aβ peptide variants with specific mutations, such as V689P/F690D/A692D for APP and V18P/F19D/A21D for Aβ42, expressed using neuron-specific promoters and AAV vectors to inhibit wt Aβ polymerization and reduce toxicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide drugs are used to prevent Aβ polymerization, then biological activity and specificity are improved, but half-life in vivo is shortened and BBB penetration is reduced
Solution Approach 1:
The patent employs endogenous neurons to self-produce and secrete the therapeutic Aβ peptide variant through gene therapy. The neurons continuously generate the peptide internally, eliminating the need for external administration and ensuring sustained therapeutic presence without relying on external peptide delivery systems that suffer from short half-lives.
Solution Approach 2:
The patent uses a viral vector as an intermediary to deliver the genetic construct encoding the Aβ peptide variant into neuronal cells. The viral vector acts as a mediator that transports the therapeutic gene across the blood-brain barrier and into target cells, where it then directs local peptide production, bypassing the limitations of direct peptide administration.
2Reliability
If peptide drugs are administered to treat Alzheimer's disease, then Aβ polymerization inhibition is improved, but administration complexity and delivery to brain are worsened
Solution Approach 1:
The therapeutic peptide is produced endogenously by modified neuronal cells that continuously synthesize and secrete the Aβ variant. This self-service approach eliminates the need for repeated external administrations, simplifying the treatment regimen while maintaining continuous therapeutic effect against Aβ polymerization.
Solution Approach 2:
The patent performs preliminary action by delivering the genetic construct into neuronal cells before the actual therapeutic effect is needed. The genetic material is established and integrated into the cellular system in advance, enabling the cells to autonomously produce the therapeutic peptide when required, rather than requiring continuous external supply.
3Reliability
If antibody therapy is used to reduce Aβ, then Aβ-reducing effect is improved, but side-effect profile and repeated intravenous administration requirements worsen
Solution Approach 1:
The patent uses a viral vector as an intermediary delivery system to transport the therapeutic gene into the central nervous system. This intermediary approach allows the therapeutic peptide to be produced locally within the brain, avoiding the need for repeated intravenous antibody administrations and their associated systemic side effects.
Solution Approach 2:
The endogenous production of the therapeutic Aβ variant by neuronal cells eliminates the need for external antibody administrations. The system serves itself by continuously producing the therapeutic peptide locally, avoiding the side-effect profile and administration burden associated with repeated intravenous antibody therapy.
Data Source
AI summary
The present invention provides a novel gene-therapeutic agent for neurodegenerative diseases. The present invention allows AB variants to be secreted out of cells to allow wt AB polymerization to be slowed or inhibited and cytotoxicity to be reduced in the human body, and thus exhibits excellent effects of preventing, alleviating, and treating neurodegenerative diseases.